Screening of potential biomarkers in hepatitis C virus-induced hepatocellular carcinoma using bioinformatic analysis

JUN LIU¹, ZHANZHONG MA¹, YANMING LIU¹, LIANGYIN WU¹, ZHIWEI HOU² and WENLI LI²

¹Department of Laboratory Medicine and ²Reproductive Medicine Center, Yue Bei People’s Hospital, Shaoguan, Guangdong 512026, P.R. China

Received December 6, 2018; Accepted June 6, 2019

DOI: 10.3892/ol.2019.10578

Abstract. Evidence suggests that hepatitis C virus (HCV) infection is among the main causes of hepatocellular carcinoma (HCC). In addition, HCV-induced HCC (HCV-HCC) exhibits adverse clinical outcomes and limited therapeutic treatments are available for this condition. To investigate key biomarkers in the occurrence and development of HCV-HCC, microarray datasets GSE62232, GSE69715 and GSE107170 were downloaded from the Gene Expression Omnibus database for analysis. The differentially expressed genes between HCV-HCC and normal tissue were identified using the GEO2R online tool. The function enrichment analyses including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were performed using the Database for Annotation, Visualization and Integrated Discovery online tool. A protein-protein interaction network was constructed using the Search Tool for the Retrieval of Interacting Genes database and visualized using Cytoscape. A total of 368 DEGs were identified, and the top 10 hub genes with a high degree of connectivity were selected for further analysis. Subsequently, overall survival and disease-free survival analysis revealed that there was a significant association between altered expression of HMMR, CCNB1 and KIF20A, and poor clinical outcome. In summary, these results indicate that HMMR, CCNB1 and KIF20A are potential targets for diagnosis and therapy of HCV-HCC.

Introduction

Hepatocellular carcinoma (HCC) is a high-incidence malignant tumor worldwide; its incidence rate is ~5.7% of all new cancer cases, and it has become the third leading cause of cancer-associated deaths (1). The chronic persistent infection of hepatitis C virus (HCV) is a major etiological element of HCC, accounting for 25% of HCC cases (2). Numerous studies have focused on the aberrant expression and alteration of genes, a number of which are involved in the development of HCC. It has been found that DNA topoisomerase 2α (TOP2A) may act as a biomarker and is a drug target of nitidine chloride in HCC (3). The increase of vascular endothelial growth factor plays a key role in the recurrence of HCC (4). Testicular nuclear receptor 4 may affect the capability of a patient to suppress HCC metastasis (5). In addition, the mRNA overexpression of the cognate receptors c-Met and epidermal growth factor receptor were found to be involved in tumor recurrence (6). However, the high mortality rate is due in part to the lack of early detection of HCC markers (7). Thus, it is vital to identify effective early diagnostic methods and to understand the molecular mechanism of HCC development, in order to intervene in the progression of the disease at the early stages.

Currently, large datasets, which include genomic sequencing, DNA copy number arrays and protein arrays, are uploaded to public databases, for example Gene Expression Omnibus (GEO) and Oncomine. Furthermore, these databases are available for screening differentially expressed genes (DEGs) and analyzing the molecular mechanism of carcinogenesis in HCC. Nevertheless, it is difficult to trust the results from separate microarray analysis. Therefore, in the present study, three mRNA microarray datasets of HCV-induced HCC (HCV-HCC) and non-tumor tissues were analyzed to identify DEGs, using the GEO2R web tool. Subsequently, the DEGs were analyzed using the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases to identify the molecular mechanisms, biological processes and pathways involved, and a protein-protein interaction (PPI) network was constructed. Finally, in total, 368 DEGs and 10 hub genes were identified, providing several possibilities to investigate as potential biomarkers for the diagnosis of HCV-HCC and for novel drug development.

Materials and methods

Microarray data. GEO (http://www.ncbi.nlm.nih.gov/geo) is a high-throughput gene expression database. In the present study, three gene expression datasets (GSE62232 (8) from France, GSE69715 (9) from Italy and GSE107170 (10) from Italy) were downloaded from GEO. GSE62232 comprised nine
HCV-HCC samples and 10 adjacent non-tumor tissue samples, GSE69715 comprised 37 HCV-HCC and 66 normal samples, and GSE107170 included 44 HCV-HCC tissue and normal tissue (Table I). All of these datasets were obtained from analyses performed using the GPL570 Affymetrix Human Genome U133 Plus 2.0 Array (Thermo Fisher Scientific, Inc.).

Identification of DEGs. GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/) is an online analysis tool that compares two or more groups of samples to identify DEGs. The DEGs of the three gene expression datasets including HCV-HCC and non-cancer samples were analyzed, and the log2 fold-change (FC) and adjusted P-values were calculated. Genes that fulfilled the criteria of log2FC ≥1.0 and adjusted P<0.05 were considered statistically significant and termed DEGs. The Venn diagram web tool (bioinformatics.psb.ugent.be/webtools/Venn/) was used to represent the overlapping DEGs from each dataset.

GO and KEGG pathway analysis of DEGs. The Database for Annotation, Visualization and Integrated Discovery (DAVID) tool (version 6.7; https://david.ncifcrf.gov/) is an online biological information database that integrates biological data and analysis tools. GO was used to perform bioinformatic analysis and annotate function enrichment of genes. KEGG is a database containing large-scale molecular datasets generated from genome sequencing, used to explore the high-level functions and utilities of the biological system. DAVID was applied to perform the function enrichment and biological analyses of these DEGs. P<0.01 and gene counts ≥10 were considered statistically significant.

PPI network of DEGs. The Search Tool for the Retrieval of Interacting Genes (STRING) database (version 10.0; http://string-db.org/) was used to construct the PPI network. Assessing the potential protein interactions enables the identification of possible mechanisms in the development of diseases. The PPI pairs with a combined score >0.4 were considered statistically significant. Cytoscape software (version 3.40; www.cytoscape.org/) was used to visualize the PPI network. CytoHubba is an application of Cytoscape, and was used for calculating the degree of each protein node.

Hub gene identification and analysis. In the present study, the top 10 genes with a high degree of connectivity from the PPI network were identified as hub genes. Hierarchical clustering of hub genes was constructed using University of California Santa Cruz Cancer genomics browser (version hg19; http://genome-cancer.ucsc.edu). The overall survival and disease-free survival time analyses with the hub genes were performed by constructing Kaplan-Meier curves in cBioPortal (version 2.2.1; http://www.cbioportal.org). The datasets of Wurmbach Liver (11) and Mas Liver (12) were obtained from the online database Oncomine (http://www.oncomine.com) and used to analyze the relationship between expression patterns and HCV status. Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/detail.php) is an online tool for analyzing gene expression data from cancer and normal tissues from The Cancer Genome Atlas and genotypetype-tissue expression projects. GEPIA and The Human Protein Atlas (https://www.proteinatlas.org), which originated in Sweden and is designed to map all the human proteins in tissues, cells and organs, were used to verify the expression of hyaluronan mediated motility receptor (HMMR), cyclin B1 (CCNB1) and kinesin family member 20A (KIF20A) in HCV-HCC (13,14).

Results

Identification of DEGs in HCV-HCC. In the present study, three mRNA microarray datasets (GSE62232, GSE69715 and GSE107170) were selected, and DEGs (1,631 in GSE62232, 1,448 in GSE69715 and 1,092 in GSE107170) were identified. The overlap among the three gene expression profiles included 368 DEGs, displayed using a Venn diagram (Fig. 1), including 264 downregulated genes and 104 upregulated genes.

GO and KEGG analyses of DEGs. Functional enrichment analyses of DEGs, including GO and KEGG pathways, were performed using DAVID (Table II). The resulting GO terms were enriched in biological processes, including ‘organic acid catabolic process’, ‘carboxylic acid catabolic process’, ‘secondary metabolic process’, ‘cellular amino acid catabolic process’, ‘amine catabolic process’, ‘cellular amino acid derivative metabolic process’, and ‘response to steroid hormone
stimulus'. Molecular function analysis results indicated that the DEGs were enriched in 'carbohydrate binding'. For the results of cell component analysis, the DEGs were mainly enriched in 'extracellular region', 'extracellular region part', and 'extracellular space'. Moreover, KEGG pathway analysis revealed that the DEGs were primarily enriched in 'metabolic pathways'.

**PPI network construction and hub gene selection.** The PPI network of the DEGs was constructed using STRING (Fig. 2A) and the top ten genes based on connectivity degree were identified using Cytoscape (Fig. 2B). The 10 genes with the highest degree of connectivity were identified as hub genes in the PPI network (Table III) 4.

**Analysis of hub genes.** The hierarchical clustering of hub genes inferred that there is a difference in gene expression between HCV-HCC samples and normal samples (Fig. 3). Subsequently, in order to identify and understand the prognostic values of the hub genes, overall and disease-free survival time analyses were performed using the Kaplan-Meier method. The results of the overall survival analysis are displayed in Fig. 4. A significant association was observed between poor prognosis and overexpression of genes CDK1, HMMR, NDC80, CCNB1, KIF20A, NEK2 and PBK, in patients with HCV-HCC. Furthermore, as shown in Fig. 5, patients with HCC and overexpression of HMMR, CCNB1 and KIF20A presented with lower disease-free survival rates. Analysis of the Wurmbach Liver and Mas Liver datasets from the Oncomine database showed that higher mRNA levels of CCNB1, KIF20A and HMMR were significantly associated with HCV-HCC (Fig. 6). GEPIA analysis of tumor vs. normal tissue demonstrated that CCNB1, KIF20A and HMMR were significantly overexpressed in HCC (Fig. 7A-C). In addition, the analysis from The Human Protein Atlas indicated that the expression of CCNB1, KIF20A and HMMR is enhanced in HCC tissue (Fig. 7D-I) (14).

**Discussion**

Persistent HCV infection has been considered to significantly increase the risk of developing HCC (15). However, following a review of the literature, few studies have attempted to describe the molecular mechanism of HCV-HCC (16-18). Due to an absence of appropriate diagnostic markers and targeted treatments, early diagnosis is challenging, and high mortality rates are observed amongst, patients with this condition (7). Consequently, it is vital to explore definitive targets for HCV-HCC.

In the present study, 10 hub genes were identified among 368 DEGs in HCV-HCC. Most notably, overexpression of CCNB1, KIF20A and HMMR were associated with poorer prognosis. CCNB1 is an important modulator of cell cycle progression (19), and it has been reported that its overexpression contributes to the regulation of invasive
Figure 2. PPI network and the most significant modules from the differentially expressed genes. (A) A PPI network was constructed using the STRING database. (B) The top 10 hub genes from the PPI network with the highest degree of connectivity. PPI, protein-protein interaction.

Figure 3. Hierarchical clustering of the hub genes was constructed using University of California Santa Cruz genomics browser. Upregulation of genes is marked in red, whereas downregulation of genes is marked in blue. TOP2A, DNA topoisomerase 2α; CDK1, cyclin dependent kinase 1; CCNB1, cyclin B1; CDKN3, cyclin dependent kinase inhibitor 3; NDC80, kinetochore complex component; CCNB2, cyclin B2; NEK2, NIMA related kinase 2; PBK, PDZ binding kinase; KIF20A, kinesin family member 20A; HMMR, hyaluronan mediated motility receptor.
overexpression of CCNB1, an independent prognostic factor, is associated with shorter recurrence-free survival time and is a potential therapeutic target (25,26). In the present study, overexpression of KIF20A was significantly associated with poor prognosis, and it was identified as a hub gene in HCV-HCC. HMMR is a multifunctional oncogenic protein (32) and many studies have reported that it is overexpressed in human leukemia types and breast cancer (33-35). Tilghman et al (36) considered that HMMR is a candidate therapeutic target in glioblastoma, and Wang et al (37) suggested that overexpression of HMMR led to a poor clinical outcome. However, few studies have reported on the role of HMMR in HCC (38), whereas the present study suggests that the gene is overexpressed in patients with HCV-HCC, and that this overexpression is significantly associated with the overall and disease-free survival. Therefore, HMMR is a potential novel candidate biomarker for HCV-HCC. According to epidemiological studies, nearly 170 million people worldwide are carriers of HCV, and have a 17-fold increased risk of developing HCC (39). HCV infection is the main cause of HCC in Latin America, Europe and Japan (40). Therefore, performing survival analyses and exploring the prognostic value of the 10 hub genes identified from the present study in cohorts with various ethnic backgrounds is important in future studies. The results of the
Figure 5. Disease-free survival time analyses of the hub genes identified in this study. Disease-free survival time analyses of the hub genes were carried out using cBioPortal, and are presented in Kaplan-Meier plots (A) CDK1. (B) HMMR. (C) NDC80. (D) CCNB1. (E) KIF20A. (F) NEK2. (G) PBK. CDK1, cyclin dependent kinase 1; HMMR, hyaluronan mediated motility receptor; NDC80, kinetochore complex component; CCNB1, cyclin B1; KIF20A, kinesin family member 20A; NEK2, NIMA related kinase 2; PBK, PDZ binding kinase.

Figure 6. Comparison of CCNB1, HMMR and KIF20A gene expression between HCV-HCC and adjacent non-tumor tissues. mRNA expression of (A) CCNB1, (B) HMMR and (C) KIF20A in hepatitis C virus-induced hepatocellular carcinoma from the Wurmbach Liver dataset (top panel) and the Mas Liver dataset (bottom panel). CCNB1, cyclin B1; KIF20A, kinesin family member 20A; HMMR, hyaluronan mediated motility receptor.
Oncomine analysis showed that overexpression of CCNB1, KIF20A and HMMR mRNA were significantly associated with HCC progression, suggesting these genes are important factors in the occurrence and development of HCV-HCC. mRNA expression of CCNB1, HMMR and KIF20A in the GEPIA database was analyzed, indicating that they were all overexpressed in HCV-HCC. However, the difference between the numbers of HCC and normal tissue samples in the GEPIA is a limiting factor in the present study. Finally, the Human Protein Atlas database, providing information on the expression of 24,000 human proteins in cells and tissues, was utilized to explore the protein expression of CCNB1, KIF20A and HMMR in HCC tissues, demonstrating significant upregulation of all of them.

Figure 7. mRNA and protein expression of CCNB1, HMMR and KIF20A in HCV-HCC. mRNA expression of (A) CCNB1, (B) HMMR and (C) KIF20A in HCV-HCC (red; n=369) compared with normal (gray; n=160) tissues. Immunohistochemistry of the CCNB1, HMMR and KIF20A based on the Human Protein Atlas (https://www.proteinatlas.org). (D) Protein expression of CCNB1 in normal tissue (not detected). (E) Protein expression of HMMR in normal tissue (not detected). (F) Protein expression of KIF20A in normal tissue (staining, low; intensity, weak; quantity, <25%). (G) Protein expression of CCNB1 in tumor tissue (staining, medium; intensity, strong; quantity, <25%). (H) Protein expression of HMMR in tumor tissue (staining, medium; intensity, strong; quantity, <25%). (I) Protein expression of KIF20A in tumor tissue (staining, high; intensity, strong; quantity, >75%). *P<0.001. CCNB1, cyclin B1; KIF20A, kinesin family member 20A; HMMR, hyaluronan mediated motility receptor; HCV-HCC, hepatitis C virus-induced hepatocellular carcinoma.
In conclusion, in the present study, 368 DEGs and 10 hub genes were identified and are potential diagnostic biomarkers and therapeutic targets for HCV-HCC. Specifically, the findings suggest CCNB1, KIF20A and HMMR as candidate targets for HCV-HCC diagnosis and therapy. However, in vitro and in vivo experiments are necessary for validation of these results.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The dataset of GSE62232, GSE69715 and GSE107170 are available from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo). The dataset of Wurmbach Liver and Mas Liver are available from Oncomine (http://www.oncomine.com).

Authors’ contributions
WLL, JL and ZZZ designed the study. JL analyzed the data and wrote the manuscript. ZWH, YML and LYW contributed to data collection, analysis and figure preparation. ZWH wrote parts of the manuscript and revised the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Zhu RX, Seto WK, Lai CL and Yuen MF: Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 10: 332-339, 2016.
2. Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luang W, Wang Q and Yee HT: Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol 12: 64, 2012.
3. Liu LM, Xiong DD, Lin F, Yang H, Dang YW and Chen G: DNA topoiso merase 1 and 2A function as oncopgenes in liver cancer and may be direct targets of nitidine chloride. Int J Oncol 53: 1897-1912, 2018.
4. Faillaci F, Macri L, Critelli R, Milosa F, Schepis F, Turolo E, Andreani S, Vandelli G, Bernabucci V, Lei B, et al: Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct acting antivirals. Hepatology 68: 1010-1024, 2018.
5. Jin J, Lin H, Li G, Xu J, Shi L, Chang C and Cai X: TR nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis 9: 283, 2018.
6. Daveau M, Scotte M, François A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF and Salier JP: Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Scand J Gastroenterol 36: 130-141, 2001.
7. Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N and Tang W: Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 22: 262-274, 2016.
8. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soursouvanh F, et al: Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47: 505-511, 2015.
9. Sekhar V, Pollicino T, Diz G, Engle RE, Alayli F, Melis M, Kabat J, Tice A, Pomerence A, Altan-Bonnet N, et al: Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma. PLoS Pathog 14: e1006916, 2018.
10. Diaz G, Engle RE, Tice A, Melis M, Montenegro R, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Bock KW, Moore IN, et al: Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma. Mol Cancer Res 16: 1406-1419, 2018.
11. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Tio Y, Fang S, Mazzaferrro V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-947, 2007.
12. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Gho bribal RM, McVier P and Fisher R: Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 15: 85-94, 2009.
13. Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45: W98-W102, 2017.
14. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Jöstendief Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science 347: 1260419, 2015.
15. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, et al: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6547-6599, 1990.
16. McGivern DR and Lemon SM: Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30: 1969-1983, 2011.
17. Lupberge J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Meszaros G, Mardinioglu A, Sivertsson Â, Kampf C, Jöstendief et al: Combined analysis of metabolomes, proteomes and transcriptomes of HCV-infected cells and liver to identify pathways associated with disease development. Gastroenterology pii: S0016-S5085(19)35670-7, 2019.
18. Wu SY, Lan SH and Liu HS: Degradative autophagy selectively regulates CCND1 (cyclin D1) and MIR224, two oncogenic factors involved in hepatocellular carcinoma tumorigenesis. Autophagy 15: 729-730, 2019.
19. Sartor H, Ehlert F, Grzeschik KH, Müller R and Adolph S: Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. Genomics 13: 911-912, 1993.
20. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, et al: Proteomics and protein expression profiling in breast cancer patients identifies novel proteins directly associated with therapy responsiveness. Mol Med 15: 365-376, 2009.
21. Song Y, Zhao C, Wang J, Jin J, Xu J, Shi L, Chang C and Cai X: TR nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis 9: 283, 2018.
25. Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D and Ling C: Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer 11: 39, 2012.

26. Li L, Lei Q, Zhang S, Kong L and Qin B: Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis. Oncol Rep 38: 2607-2618, 2017.

27. Miki H, Setou M, Kaneshiro K and Hirokawa N: All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA 98: 7004-7011, 2001.

28. Kawai Y, Shibata K, Sakata J, Suzuki S, Utsumi F, Niimi K, Sekiya R, Senga T, Kikkawa F and Kajiyama H: KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear-cell carcinoma cells. Oncol Rep 40: 195-205, 2018.

29. Shi C, Huang D, Lu N, Chen D, Zhang M, Yan Y, Deng L, Lu Q, Lu H and Luo S: Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget 7: 26206-26219, 2016.

30. Maxwell CA, McCarthy J and Turley E: Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci 121: 925-932, 2008.